Kaito Biologics Unveils China's Scarce End-to-End Plasmid-mRNA-LNP GMP CDMO Facility in Wuhan
Catug
One-stop CDMO Service Provider
1A Rare End-to-End Industrialization Service Platform in China for Plasmid, mRNA, LNP, and Final Drug Products
2Catug Speed – Design, Construction, and Validation Completed in 4.5 Months
3Central China’s First mRNA GMP Production Line, Compliant with Chinese and U.S. Clinical Filing Standards
4Internationally Advanced mRNA Technology Platform, Senior Professional Team for One-Stop Service
On October 20, the inauguration ceremony of Catug’s mRNA GMP manufacturing facility in Wuhan was officially held at the Wuhan Optics Valley Bio-city. Government officials, including Feng Li, Deputy Director of the Administration Committee of the East Lake High-Tech Development Zone, and Yan Xingchun, First-Level Researcher of the East Lake High-Tech Development Zone and Director of the Construction and Financing Division of the Wuhan National Biological Industry Base Construction Service Center, along with representatives from park enterprises, partners, and investors, were invited to attend the ceremony. Dr. Wang Xiao, Co-founder and CEO of Catug, and Dr. Ren Keyun, Co-founder and General Manager of Catug, attended the event.
At the ceremony, Dr. Ren Keyun, on behalf of the Catug team, delivered a welcome address to the attending leaders and guests, and shared an update on the company’s development.
In August 2021, Catug established its presence and base in Wuhan Optics Valley Biological City. It currently operates a 4,700 m² R&D center and industrialization production lines, including a GMP facility with a total area of 3,000 m². Equipped with technology transfer areas, GMP workshops, and quality control laboratories, the fully functional facilities provide end-to-end coverage from plasmids to mRNA, LNP, and final products, thereby accelerating the efficiency of project transfer and incubation.
Among these, the plasmid DNA GMP production line was put into operation in early 2022. Leveraging its robust capabilities in plasmid DNA process development and manufacturing, Catug has successfully fulfilled deliveries of plasmids at various grades for multiple clients.
The newly commissioned mRNA and LNP GMP production lines enable an end-to-end manufacturing process, spanning from plasmid preparation and mRNA synthesis to LNP formulation and final product filling. These facilities provide GMP manufacturing services for mRNA vaccines and therapeutics that comply with clinical submission standards in both China and the United States.
Feng Li, Deputy Director of the Administrative Committee of East Lake High-Tech Development Zone, took the stage to deliver a speech and cut the ribbon for the official launch of Catug’s mRNA GMP facility in Wuhan. Other guests participating in the ribbon-cutting ceremony included Yan Xingchun, First-Level Researcher of East Lake High-Tech Development Zone and Director of the Construction and Financing Division at the Wuhan National Bio-industry Base Construction Service Center; Mr. Deng Xiafei, President of Humanwell Healthcare Group; Dr. Wang Xiao, Co-founder and CEO of Catug; Dr. Ren Keyun, Co-founder and General Manager of Catug; Dr. Lu Tinglin, Vice President of Yuansheng Capital; and Mr. Duan Chengcai, Vice President of Quality Management at Catug.
Dr. Lu Tinglin, Director of Catug and Vice President of Yuansheng Capital, and Mr. Zhai Zhou, President of the Wuhan Donghu Sub-branch of China CITIC Bank, took the stage one after another to deliver remarks, extending their congratulations on the completion of Catug’s mRNA GMP facility in Wuhan.
At the inauguration ceremony, Dr. Hui Aimin, a senior expert in the mRNA field and former President of Fosun Pharma’s Global R&D Center, delivered a keynote presentation titled “mRNA – COVID-19 Vaccines and the Future,” providing an in-depth analysis of industry trends.
Catug is committed to building an advanced process technology platform and establishing stable, high-quality upstream and downstream ecosystem partnerships. At the inauguration ceremony, Catug entered into strategic collaborations with Precision NanoSystems (PNI), Duoning Biotech, Tangzhi Pharma, and Bailinke Pharmaceutical Equipment.
In the future, Catug will continue to deliver high-quality services, fostering partnerships built on mutual trust and win-win outcomes through professionalism and innovative concepts. By accelerating technological advancements in nucleic acid and gene therapy, Catug aims to make advanced therapies accessible to the general public.